Bipolar Disorder

Bipolar depression does not have a single face. Through one patient’s journey, this case-based reflection explores 5 distinct presentations and how each can shape clinical recognition and treatment.

Learn why varenicline leads smoking cessation products in bipolar disorder, with reassuring safety data and practical strategies when quitting proves difficult.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

DSM's real weakness isn't categories—it's weak science. Explore when disorders are diseases vs dimensions, and why overlap misleads.

Learn how clinicians manage bipolar disorder in women who may become pregnant—safer meds, contraception counseling, and relapse prevention.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.

Clinicians explore neuroscience-guided off-label prescribing.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Phase 2 study tests AL001 brain-targeted lithium in bipolar I, aiming to cut toxicity and monitoring via advanced MRI/MRS imaging.